<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264078</url>
  </required_header>
  <id_info>
    <org_study_id>antiCD7-UCAR-T</org_study_id>
    <nct_id>NCT04264078</nct_id>
  </id_info>
  <brief_title>Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies</brief_title>
  <official_title>Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Shanghai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital Of Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Kunming Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The General Hospital of Western Theater Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is&#xD;
      poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19&#xD;
      CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell&#xD;
      hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target&#xD;
      expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical&#xD;
      experiments is cheerful.however, how to select the functional T cells from the malignant T&#xD;
      cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the&#xD;
      majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of&#xD;
      the host as the material of anti-CD7 universal CAR-T cells could be accessible and&#xD;
      affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell&#xD;
      hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the anti-tumor efficiency of anti-CD7 UCAR-T cells</measure>
    <time_frame>4 weeks after infusion</time_frame>
    <description>ratio of bone marrow blast cells and/or the measurable lesion size and standralized uptake value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the long-term efficiency of anti-CD7 UCAR-T cells</measure>
    <time_frame>3 and 6 months after infusion</time_frame>
    <description>ratio of bone marrow blast cells and/or the measurable lesion size and standralized uptake value</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>T-cell Leukemia</condition>
  <condition>T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>anti-CD7 UCAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD7 UCAR-T cells</intervention_name>
    <description>Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg</description>
    <arm_group_label>anti-CD7 UCAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m^2 per day for 6 days</description>
    <arm_group_label>anti-CD7 UCAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoxan</intervention_name>
    <description>600mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline</description>
    <arm_group_label>anti-CD7 UCAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline</description>
    <arm_group_label>anti-CD7 UCAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute&#xD;
             lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including&#xD;
             Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma&#xD;
             (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral&#xD;
             T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell&#xD;
             leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal&#xD;
             NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB or higher))&#xD;
&#xD;
             2. CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry or&#xD;
             immunohistochemistry (tissue)）&#xD;
&#xD;
             3. Hgb ≥ 7.0 (can be transfused)&#xD;
&#xD;
             4. Life expectancy greater than 12 weeks&#xD;
&#xD;
             5. Informed consent explained to, understood by and signed by the patient/guardian.&#xD;
             Patient/guardian is given a copy of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating.&#xD;
&#xD;
          2. Tumor in a location where enlargement could cause airway obstruction (per investigator&#xD;
             discretion).&#xD;
&#xD;
          3. Active infection with HIV or HTLV.&#xD;
&#xD;
          4. Clinically significant viral infection or uncontrolled viral reactivation of&#xD;
             EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human&#xD;
             herpesvirus)-6.&#xD;
&#xD;
          5. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial&#xD;
             infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT,&#xD;
             per investigator discretion. Cardiac echocardiography with LVSF (left ventricular&#xD;
             shortening fraction)&lt;30% or LVEF(left ventricular ejection fraction)&lt;50%; or&#xD;
             clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart&#xD;
             Association) III or IV (Confirmation of absence of these conditions on echocardiogram&#xD;
             within 12 months of treatment).&#xD;
&#xD;
          6. CNS abnormalities: Presence of CNS(central nervous system)-3 disease defined as&#xD;
             detectable cerebrospinal blast cells in a sample of CSF(cerebrospinal fluid) with ≥ 5&#xD;
             WBC( white blood cell)s per mm3 (unless negative by the Steinherz/Bleyer algorithm);&#xD;
             Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular&#xD;
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS&#xD;
             involvement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinqiao Hospital of Chongqing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Zhang, MD</last_name>
    <phone>+8613808310064</phone>
    <phone_ext>+8613808310064</phone_ext>
    <email>zhangxxi@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruihao Huang</last_name>
    <phone>+8618984398751</phone>
    <phone_ext>+8618984398751</phone_ext>
    <email>1169731117@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Xinqiao Hospital</name>
      <address>
        <city>ChongQing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Zhang, MD</last_name>
      <phone>+8613808310064</phone>
      <phone_ext>+8613808310064</phone_ext>
      <email>zhangxxi@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruihao Huang</last_name>
      <phone>+8618984398751</phone>
      <phone_ext>+8618984398751</phone_ext>
      <email>1169731117@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Xi Zhang, MD</investigator_full_name>
    <investigator_title>Chef of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

